Veterinary Biologics Market

Overview

The global Veterinary Biologics Market was valued at USD 14.2 billion in 2025 and is projected to reach USD 25.7 billion by 2034, growing at a CAGR of 6.8% during the forecast period (2026–2034). The market is driven by the rising incidence of transboundary and zoonotic livestock diseases, expanding pet ownership, stricter food safety and biosecurity expectations, and a growing preference for preventive vaccination and targeted antibody therapy over reactive antibiotic treatment across cattle, poultry, swine, and companion animal practices. The market is shifting from conventional killed and live attenuated vaccines toward recombinant vector, subunit, and RNA-particle platforms that can be updated within weeks when a new pathogen strain appears. In companion animals, long-acting monoclonal antibodies for pain, allergy, and infectious disease are moving biologics beyond prevention into chronic disease management.  Government initiatives such as the European Union's Regulation (EU) 2019/6 on veterinary medicinal products, applied since January 2022, are harmonizing authorization rules for vaccines and biologics across member states. The United States Department of Agriculture's Center for Veterinary Biologics continues to use conditional licensing and platform technology guidance to shorten the path for emerging disease vaccines, while India's National Animal Disease Control Programme funds mass vaccination of livestock against foot-and-mouth disease and brucellosis. By Region, North America held the largest share of the market in 2025, accounting for 40% of global revenue, supported by a large cattle and companion animal base, high veterinary spend per animal, and an established licensing system. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding livestock production, rising pet adoption in China and India, and wider swine and poultry vaccination.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Platform-Based and RNA-Particle Vaccine Technologies Emerging as a Transformational Trend

• Veterinary vaccine developers are moving from pathogen-specific manufacturing to platform systems, in which a validated production process stays fixed and only the antigen gene changes. This approach cuts development time from years to weeks and lets producers respond to new strains during an outbreak instead of after it, with a lighter data package for each new antigen.
• Recombinant vector, subunit, and nucleic acid vaccines are replacing whole-pathogen products in poultry, swine, and companion animals. These platforms avoid handling live virulent organisms during manufacturing, support clear separation of vaccinated and infected animals, and fit the surveillance rules that importing countries apply to livestock trade. Veterinarians also gain products with cleaner safety profiles.
• Herd-specific prescription vaccines, supervised by veterinarians, are gaining ground in swine, cattle, and deer operations where circulating strains differ from farm to farm. Sequencing of isolates collected on the farm now guides antigen selection, which links diagnostics directly with vaccine design and shortens the gap between detection and protection for affected herds and nearby farms.
• Merck Animal Health received United States Department of Agriculture approval for Nobivac NXT Canine Flu H3N2 in June 2024, described by the company as the first canine influenza vaccine built on its RNA-particle platform. The nonadjuvanted, low-volume 0.5 mL dose is indicated for healthy dogs eight weeks of age or older.

KEY MARKET DRIVER

Rising Burden of Transboundary and Zoonotic Animal Diseases Driving Market Growth

• Outbreaks of foot-and-mouth disease, African swine fever, highly pathogenic avian influenza, and peste des petits ruminants cause direct livestock losses and trigger trade bans that hurt producers more than the disease itself. Vaccination is the main tool for diseases without a cure, so each major outbreak lifts demand for licensed vaccines in affected and neighboring countries.
• Food safety and antimicrobial stewardship policies are pushing producers to prevent disease rather than treat it. Biologics reduce the need for antibiotics in calves, piglets, and broilers, and retailers in export markets increasingly ask for documented vaccination programs as part of supplier audits. Regulators in several regions have also tightened limits on routine antibiotic use in food animals.
• Zoonotic exposure adds a public health reason to vaccinate animals. Rabies in dogs, brucellosis in cattle, and avian influenza in poultry all pass to people, so governments fund mass vaccination campaigns, and the World Organisation for Animal Health sets standards that national veterinary authorities follow when they monitor vaccine programs.
• Zoetis received a conditional license from the United States Department of Agriculture's Center for Veterinary Biologics in February 2025 for an H5N2 killed-virus avian influenza vaccine for chickens. The company stated that it was designed to match circulating H5 strains and showed a reasonable expectation of efficacy against current H5N1 strains.

KEY MARKET OPPORTUNITY

Expansion of Monoclonal Antibody Therapies for Chronic Conditions in Companion Animals Creating New Revenue Streams

• Companion animal owners are spending more on long-term care, which opens room for antibody therapies that treat chronic pain, itch, and infectious disease through scheduled injections instead of daily tablets. Clinics value the visit-based dosing model because it improves treatment adherence and builds recurring revenue. Owners also welcome fewer daily doses at home.
• Older dogs and cats are a largely undertreated group for degenerative joint disease, and dermatology and parvovirus care still rely heavily on small-molecule drugs and supportive treatment. Species-specific antibodies address these gaps with targeted action, which supports premium pricing and clear separation from generic products. Clinics also gain a distinct service line for senior pet care.
• Emerging markets in Asia-Pacific and Latin America offer a second opportunity, as rising pet ownership and growing clinic networks create first-time demand for biologics. Local manufacturing partnerships and regional registrations can lower costs and bring antibody and vaccine products to price-sensitive buyers. Distributors in these regions also provide cold-chain reach that new entrants lack.
• Zoetis reported in February 2025 that more than one million dogs in the United States had been treated with Librela since its October 2023 launch. Librela is a monoclonal antibody that targets nerve growth factor to control osteoarthritis pain in dogs, and the company updated its label that month based on post-approval experience.

Veterinary Biologics Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product Type

Vaccines held the largest market share in 2025 because they are the standard preventive tool across every major livestock and companion animal species. Routine immunization schedules for cattle, poultry, swine, dogs, and cats create steady repeat demand, and national control programs for foot-and-mouth disease, rabies, Newcastle disease, and porcine respiratory diseases buy vaccines in large volumes. Producers value vaccines for their lower per-animal cost compared with therapeutic biologics, while export markets expect documented vaccination records as part of health certification. Continuous improvement in vector, subunit, and inactivated formulations also keeps the replacement cycle active, as new products offer broader strain coverage, fewer injection-site reactions, and fewer doses per animal.

Monoclonal Antibodies are projected to grow at the fastest CAGR during the forecast period because they move biologics from prevention into the treatment of chronic and acute disease. Antibodies for osteoarthritis pain, canine allergic dermatitis, and canine parvovirus have shown that a single targeted injection can replace daily medication or shorten hospital stay, which pet owners and clinics accept readily. Longer-acting formats that cover several months per dose, higher cell-line yields, and expanding manufacturing capacity are lowering the cost per dose. Regulators in the United States, Europe, and Canada have approved species-specific antibodies, which gives developers a clearer pathway for new targets in dogs and cats.

Product Type categories include

• Vaccines (Dominating Segment)
• Monoclonal Antibodies (Highest CAGR Segment)
• Antisera
• Immunomodulators
• Others

Analysis by Animal Type

Cattle held the largest market share in 2025 because the species carries a heavy disease burden across dairy and beef production and is covered by one of the widest vaccine ranges in veterinary medicine. Respiratory disease complexes, scours in calves, clostridial infections, reproductive diseases, and mastitis all have licensed biologics, and large herd sizes multiply the number of doses used per farm. Dairy and feedlot operators track losses closely, and the cost of a single outbreak far exceeds vaccine spending, which keeps vaccination programs in budgets even when cattle prices fall. Government-run campaigns for foot-and-mouth disease and brucellosis add further volume in Asia, Africa, and Latin America.

Dogs are projected to grow at the fastest CAGR during the forecast period because dog owners are the main buyers of premium biologics in veterinary clinics. Humanization of pets, longer canine life spans, and growing insurance coverage are raising treatment spend, and dogs are the first species for most new antibody and RNA-particle vaccine launches. Canine influenza, leptospirosis, and parvovirus remain active disease threats in dense urban areas, which supports vaccination even in households that previously skipped boosters. Veterinary clinics are also adding wellness plans that bundle vaccines and injectable therapies, which improves compliance and repeat visits.

Animal Type categories include

• Cattle (Dominating Segment)
• Dogs (Highest CAGR Segment)
• Poultry
• Swine
• Cats
• Others

Analysis by Route of Administration

Injectable biologics held the largest market share in 2025 because subcutaneous and intramuscular delivery gives accurate dosing and reliable immune responses for most vaccines, antibodies, and antisera. Veterinarians and farm staff are trained in injection techniques, and automated injection equipment is common in hatcheries, swine barns, and feedlots. Monoclonal antibodies and adjuvanted inactivated vaccines need injection to reach the target tissue or to trigger a strong immune response, so the shift toward antibody therapy adds further injectable volume. Regulatory data packages for injectable products are also the most established, which shortens approval timelines for line extensions and combination products.

In-Ovo administration is projected to grow at the fastest CAGR during the forecast period because it delivers vaccines to the embryo at the hatchery, which gives early protection before chicks reach the farm. Large integrators favor the method as it removes handling of individual chicks and delivers uniform dosing through automated injection machines. Recombinant vector vaccines for Marek's disease, Newcastle disease, and infectious bursal disease are well suited to this route, and combination products allow several diseases to be covered in one injection. Rising global poultry output and labor shortages in hatcheries are further pushing integrators to adopt in-ovo systems.

Route of Administration categories include

• Injectable (Dominating Segment)
• In-Ovo (Highest CAGR Segment)
• Oral
• Intranasal
• Others

Analysis by End User

Livestock Farms held the largest market share in 2025 because commercial dairy, beef, swine, and poultry operations buy biologics directly or through veterinarians in very large volumes. Integrated poultry and pork producers run fixed vaccination calendars for every flock or batch, and farm-level programs are reviewed by on-farm veterinarians who adjust protocols to disease pressure. Group purchasing, bulk packaging, and cost-per-animal accountability favor farms that standardize vaccination programs. Biosecurity audits from retailers and export buyers also require documented immunization, which keeps spending consistent across production cycles. Farms in Asia-Pacific and Latin America are adding capacity quickly, which widens the base of regular buyers.

Veterinary Clinics are projected to grow at the fastest CAGR during the forecast period because most new biologics for dogs and cats are launched through clinic channels first. Clinics administer antibody injections, run vaccination reminders, and sell wellness plans that lock in repeat visits, which improves both treatment adherence and revenue per client. Corporate clinic groups are expanding in North America, Europe, and urban Asia, and their purchasing scale helps them stock a wider range of biologics. Rising pet insurance penetration also lowers the cost barrier for owners, which supports higher use of premium injectable therapies.

End User categories include

• Livestock Farms (Dominating Segment)
• Veterinary Clinics (Highest CAGR Segment)
• Veterinary Hospitals
• Research Institutes
• Others

By Region

North America held the largest market share in 2025, because of its large cattle, swine, and poultry industries, high spending on companion animal care, and a mature licensing system. The United States leads regional demand, where the Virus-Serum-Toxin Act gives the USDA Center for Veterinary Biologics authority over vaccine licensing, and conditional licenses are used to speed up products for emerging threats. Canada regulates veterinary biologics through the Canadian Food Inspection Agency, and Mexico relies on SENASICA oversight, with its poultry and swine producers adding steady vaccine volume. Pet vaccination rates, early adoption of monoclonal antibodies, and a dense network of corporate veterinary clinics keep average spending per animal above other regions.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, supported by expanding livestock production, rising pet ownership, and stronger government animal health programs. China's compulsory immunization policy for diseases such as foot-and-mouth disease and avian influenza creates large, recurring vaccine volumes, while domestic manufacturers are upgrading plants to meet newer veterinary good manufacturing practice standards. India is adding capacity in poultry, rabies, and foot-and-mouth disease vaccines as dairy and poultry output rises. Japan and South Korea show higher uptake of companion animal vaccines and antibody therapies, backed by strict animal health regulation, and Southeast Asian nations within the rest of the region are building swine disease control programs.

Countries and Regions Covered

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• Germany (Largest Country Market)
• France
• United Kingdom
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin AmericaMiddle East & Africa

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The Veterinary Biologics Market is consolidated, with a small group of global animal health companies such as Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, and Ceva holding broad portfolios across livestock and companion animals, while regional manufacturers in India, China, Latin America, and Europe compete on price and local registrations. Success depends on regulatory licensing, cold-chain distribution, manufacturing quality, and veterinarian relationships. Leading companies are prioritizing monoclonal antibody pipelines, platform vaccine technologies, hatchery and farm delivery systems, and manufacturing expansion near key markets. Partnerships between developers and distributors, licensing agreements for regional rights, and selective acquisitions of vaccine and diagnostic firms are common ways to enter new species and geographies.

Key Players

• Zoetis Inc. (US)
• Merck Animal Health (US)
• Boehringer Ingelheim (Germany)
• Elanco Animal Health (US)
• Ceva Santé Animale (France)
• HIPRA (Spain)
• Virbac (France)
• Biogénesis Bagó (Argentina)
• Phibro Animal Health Corporation (US)
• Indian Immunologicals Limited (India)
• Medgene (US)
• ImmuCell Corporation (US)
• Hester Biosciences Limited (India)
• Huvepharma (Bulgaria)
• Kyoritsu Seiyaku Corporation (Japan)

Recent Market Developments

• In October 2025, Zoetis received Health Canada approval for Lenivia (izenivetmab injection) for the alleviation of osteoarthritis pain in dogs, which the company described as the world's first monoclonal antibody to provide three months of pain relief in dogs with one injection. The approval adds a long-acting option to the canine antibody segment and moves treatment from monthly to quarterly dosing.
• In December 2025, Elanco received USDA approval for Befrena (tirnovetmab), an anti-IL-31 monoclonal antibody injection for canine allergic and atopic dermatitis, with a recommended dosing interval of six to eight weeks. The approval expands antibody-based dermatology options for veterinary clinics, and Elanco began a phased US launch in May 2026.
• In July 2026, Medgene introduced the first prescription platform vaccine in the United States that targets Theileria orientalis Ikeda in cattle, a tick-borne parasite spreading with the Asian longhorned tick. The vaccine is given as a two-dose series under veterinary prescription and widens the use of platform vaccines into parasite control.
• In September 2026, The Bureau of Animal Industry in the Philippines approved the commercial sale of AVAC ASF LIVE, a live attenuated, gene-deleted vaccine developed by AVAC Vietnam, as the first African swine fever vaccine cleared for fattening pigs in the country. A second candidate from South Korea, PROVAC, is under testing, which points to growing vaccine choice for swine producers in Asia.

Frequently Asked Questions